biotech-startups-rethinking-supply-chains-2026
Marketplace procurement for the lab bench
Inside the $2.3 Billion Problem: How Biotech Startups Are Rethinking Supply Chains
The Two-Billion-Dollar Bottleneck
According to Deloitte’s most recent analysis, the average cost of bringing a single new drug to market has climbed to $2.3 billion. That figure accounts for the full lifecycle — discovery, preclinical testing, clinical trials, regulatory approval, and post-market surveillance. For a Series A biotech running on $30 million in venture capital, every inefficiency in the operation compounds into months of lost runway and delayed breakthroughs.
What most people outside the industry don’t realize is how much of that cost has nothing to do with science. A significant and growing portion of early-stage biotech spending goes to procurement — the unglamorous work of sourcing reagents, negotiating with suppliers, managing purchase orders, and reconciling invoices. For companies racing to prove a therapeutic hypothesis before the money runs out, the back office has become a surprisingly dangerous bottleneck.
The result is a wave of digital procurement platforms entering the life sciences space, promising to do for lab purchasing what Amazon Business did for office supplies. The difference is that the stakes here involve human health, and the complexity of scientific supply chains makes general-purpose solutions inadequate.
The Old Way Is Broken
Walk into any early-stage biotech and ask a researcher about ordering supplies. The response is almost always the same: frustration.
The typical lab environment involves managing relationships with 50 to 100 or more individual vendors, each with its own portal, catalog, pricing structure, and ordering process. A single researcher might need antibodies from one supplier, cell culture media from another, and custom oligonucleotides from a third — all before lunch. Each order requires navigating a separate website, creating or maintaining a separate account, and often submitting a manual purchase order that routes through a finance team already stretched thin.
Industry surveys bear this out. According to recent reporting from Entrepreneur UK, 67 percent of laboratory professionals say they would not recommend their current ordering process to a colleague. Even more striking, 89 percent report that experiments have been delayed due to backorders or supply chain disruptions — a statistic that carries real consequences when your burn rate is $800,000 a month.
The numbers on the administrative side are equally grim. Procurement teams at small biotechs report spending upward of 20 hours per week on order management alone. Onboarding a new supplier — the kind of routine task that happens dozens of times a year — takes an average of 16 to 26 days when legal, compliance, and finance all need to sign off. For a 15-person startup trying to hit an IND filing deadline, those aren’t just inconveniences. They’re existential threats to the timeline.
The Marketplace Model Arrives in the Lab
The concept is straightforward: instead of maintaining dozens of vendor relationships, researchers access a single platform that aggregates suppliers, standardizes ordering, and consolidates invoicing. Think of it as a procurement layer that sits between the lab and the supply chain, handling the complexity so scientists don’t have to.
Several companies are building in this space. Quartzy has carved out a niche in lab management and ordering for academic and small commercial labs. Labviva focuses on enterprise procurement integration. Scientist.com operates a marketplace for outsourced research services. Each approaches the problem from a slightly different angle, but the underlying thesis is the same: scientific procurement is ripe for platform-level disruption.
The company that has attracted the most attention — and capital — is ZAGENO, a dual-headquartered operation based in Boston and Berlin. Founded to build what it calls a “life science marketplace,” ZAGENO now aggregates more than 50 million SKUs from over 6,000 suppliers onto a single platform. In March 2025, the company closed a $60 million funding round led by General Catalyst, bringing its total raised to more than $88 million. That kind of backing signals that investors see lab procurement not as a niche vertical but as a category-defining opportunity.
The platform’s value proposition goes beyond simple aggregation. ZAGENO offers standardized onboarding, consolidated purchase orders, centralized invoicing, and analytics dashboards that give finance teams visibility into spending patterns across the entire organization. For a CFO trying to understand why the antibody budget tripled last quarter, that kind of transparency is transformative.
Case Study: How Apogee Therapeutics Reclaimed 250 Hours
The theoretical benefits of marketplace procurement become concrete when you look at actual deployments. Apogee Therapeutics, a Massachusetts-based biotech focused on developing antibody therapies for immunological and inflammatory diseases, offers one of the clearest examples.
Before adopting a consolidated procurement approach, Apogee managed relationships with 98 individual vendors. Each vendor relationship meant a separate account, separate invoicing, and separate reconciliation workflows. The administrative overhead was substantial — not just for the procurement team, but for researchers who were spending hours each week on what amounted to shopping and paperwork.
After consolidating onto a marketplace platform, the results were immediate and measurable. Apogee reduced its purchase order volume by 40 percent, not because it was buying less, but because orders were being routed through a single system rather than scattered across dozens of portals. The company estimates it saved more than $200,000 in staff time during the first year — time that had previously been absorbed by order management, vendor communication, and invoice reconciliation.
The research team recovered more than 250 hours in year one. That’s roughly six weeks of full-time work redirected from procurement tasks back to the lab bench. For a company in the clinical development stage, where every month of delay can cost millions, that kind of time recovery translates directly into competitive advantage.
The finance team saw its own gains. Faster supplier onboarding and consolidated invoicing saved an estimated $60,000 in reconciliation and processing costs. More importantly, the centralized spending data gave leadership real-time visibility into where money was going — the kind of insight that matters when you’re reporting to a board of investors who want to know exactly how their capital is being deployed.
The Procurement Models That Are Emerging
The marketplace approach isn’t one-size-fits-all. As the space matures, distinct procurement models are emerging based on company size, stage, and operational complexity.
Early-stage biotechs — teams of 5 to 20 running lean on seed or Series A funding — tend to benefit most from full marketplace adoption, where the platform essentially replaces the procurement function entirely. There’s no procurement team to integrate with; the platform becomes the procurement team.
Mid-stage companies with established purchasing workflows are more likely to adopt a hybrid model, using marketplace platforms for catalog purchasing while maintaining direct relationships with strategic suppliers for high-volume or custom orders. The key here is integration with existing ERP and financial systems, which is where the technical complexity increases significantly.
Large pharma organizations, meanwhile, are watching the space closely but moving cautiously. Their procurement infrastructure is deeply embedded in enterprise systems from SAP, Oracle, and Coupa. For these organizations, the marketplace model is more likely to enter as a complement to existing systems rather than a replacement — a specialized channel for long-tail purchases that don’t justify the overhead of a formal vendor relationship.
Where AI Meets the Lab Bench
The current wave of procurement platforms is solving today’s problem: aggregation, consolidation, and visibility. But the next wave is already taking shape, and it’s built on artificial intelligence.
PwC projects that 70 percent of procurement processes will be digitalized by 2027. Gartner goes further, forecasting that 70 percent of large organizations will adopt AI-driven supply chain forecasting by 2030. In the life sciences context, that means procurement platforms won’t just process orders — they’ll anticipate them.
The applications are compelling. Predictive ordering systems could analyze a lab’s historical consumption patterns, correlate them with active experimental protocols, and automatically reorder supplies before they run out. Automated reordering could eliminate the stockout problem that currently delays 89 percent of experiments. Supply chain forecasting could flag disruptions weeks in advance, giving procurement teams time to source alternatives before a critical reagent goes on backorder.
Florian Wegener, who has been at the center of the lab procurement transformation, puts it directly: “In science, every hour counts. The next generation of procurement technology is about giving researchers more time to push discovery forward and drive product cost savings.”
That framing — procurement as a research enablement function rather than a back-office cost center — represents a fundamental shift in how biotech companies think about operations. When your entire business depends on the speed and quality of scientific discovery, anything that takes researchers away from the bench is a strategic liability.
The Bigger Picture
The biotech procurement problem is, in many ways, a microcosm of a larger transformation happening across knowledge-intensive industries. When the core work requires deep expertise and intense focus — whether that’s drug discovery, software engineering, or clinical research — administrative friction isn’t just annoying. It’s economically destructive.
The $2.3 billion drug development figure from Deloitte isn’t going down anytime soon. The science is getting more complex, regulatory requirements are expanding, and the diseases that remain unsolved are the hardest ones. But if the procurement layer can be compressed — if the 20 hours per week spent on ordering can become two, if the 250 hours lost to vendor management can be redirected to the lab — then the effective cost of discovery drops, even as the headline number climbs.
For early-stage biotechs burning through venture capital on a fixed timeline, that compression isn’t optional. It’s survival. The companies that figure out how to spend less time buying things and more time discovering them are the ones that will still be around when the next funding round closes.
The marketplace model won’t solve every problem in biotech. It won’t make clinical trials cheaper or regulatory pathways faster. But it will give researchers something they desperately need and rarely get enough of: time. In an industry where a single breakthrough can change millions of lives, that might be the most valuable procurement outcome of all.
Learn more: go.zageno.com · LinkedIn · X
